Clinical High Risk for Psychosis Clinical Trial
Official title:
Optimizing Cognitive Training to Improve Functional Outcome in Clinical High Risk (CHR)
Verified date | December 2022 |
Source | Rush University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This project is a randomized-controlled trial to test the efficacy of computer-based targeted cognitive training (TCT) versus a placebo intervention of commercial computer games in adolescent/young adults at clinical high risk (CHR) for psychosis. TCT is designed to optimize learning-induced neuroplasticity in vulnerable neurocognitive systems. A main aim is to test the hypothesis that this neuroscience-guided TCT intervention will improve neural function, and that these neural improvements will improve cognition and functional outcome. CHR participants will be randomly assigned to 40 hours of TCT or placebo computer games completed within 10 weeks. TCT consists of 20 hours of training in cognition, including processing speed, memory, attention, and cognitive control followed by 20 hours of training in social cognition including affect recognition and theory of mind. Neuroimaging, cognition, social cognition, clinical symptoms, and functional status will be assessed at baseline, after 20 hours/5 weeks of cognitive training (mid-intervention), and after 20 hours/5 weeks of social-cognitive training (post-intervention). Cognition, social cognition, symptoms, and functioning will also be assessed at a 9 month follow-up (i.e. 9 months after intervention completion). We predict that TCT will lead to improvements in neurocognitive function and functional status. The results of this study will provide important information about a benign, non-pharmacological intervention for improving cognition and functional outcome in CHR individuals.
Status | Completed |
Enrollment | 139 |
Est. completion date | February 15, 2021 |
Est. primary completion date | November 23, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 30 Years |
Eligibility | Inclusion Criteria: - English speaking - One or more psychosis-risk syndromes as defined by the Structured Interview for Psychosis-Risk Syndromes (SIPS) Exclusion Criteria: - Intelligence Quotient (IQ) < 70 - Major medical illness or neurological disorder - Lifetime history of Axis I psychotic disorder and/or clear evidence that psychosis-risk syndrome is due to non-schizophrenia-spectrum Axis I or Axis II disorder |
Country | Name | City | State |
---|---|---|---|
United States | Rush University Medical Center | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Rush University Medical Center | Beth Israel Deaconess Medical Center, Harvard Medical School (HMS and HSDM), National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery | Behavioral assessment of cognition | Change in cognition from baseline (pre-intervention) to 10 weeks (post-intervention) | |
Secondary | Global Function: Social and Role Scales | Behavioral assessment of daily functioning | Change in functioning from baseline (pre-intervention) to 10 weeks (post-intervention) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03829527 -
Evaluation of the Treatment Approach ROBIN
|
N/A | |
Recruiting |
NCT05827900 -
Metacognitive Training in Ultra-high Risk
|
N/A | |
Recruiting |
NCT02951208 -
tDCS Coupled With Virtual Rehabilitation for Negative Symptoms in At-Risk Youth
|
N/A | |
Completed |
NCT03983421 -
Feasibility of an Early Detection Program for Early Psychosis on a College Campus
|
||
Recruiting |
NCT06037993 -
Endocannabinoid Activity Remodulation for Psychosis Liability in Youth
|
N/A | |
Completed |
NCT04444180 -
The Predictive Role of Self-representation in Transition of Individuals at Clinical High Risk for Psychosis
|
||
Terminated |
NCT02047539 -
Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis
|
Early Phase 1 | |
Recruiting |
NCT05114733 -
Individualized Vocational and Educational Support and Training for Clinical High Risk for Psychosis (InVEST)
|
N/A | |
Completed |
NCT03303456 -
Using Mobile Technology to Enhance Early Psychosis Treatment Delivery
|
N/A | |
Completed |
NCT03286595 -
Smartphone Applications Youth With Early Psychosis in Community Outpatient Settings
|
N/A | |
Terminated |
NCT02557945 -
Gabapentin in Patients at Clinical Risk for Psychosis
|
Phase 1/Phase 2 | |
Completed |
NCT03321617 -
Glutamate Reducing Interventions in Schizophrenia
|
Phase 1 |